USP16

Across TCGA pan-cancer cohorts, USP16 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of USP16’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where USP16 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types USP16 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

LUAD, PDAC, and HNSC are the cancer types where USP16 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in USP16 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.234	<.001	9	view →
PDAC	Male	All	−0.433	<.001	8	view →
HNSC	Male	IV	−0.184	<.001	8	view →
LSCC	Male	II,III,IV	+0.195	<.001	7	view →
COAD	All	All	−0.137	.008	4	view →
CCRCC	All	II,III,IV	+0.059	.033	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

USP16–LUAD

Open the LUAD breakdown →